Advertisement

Pharmacologic Management of Excessive Daytime Sleepiness

Published:September 07, 2022DOI:https://doi.org/10.1016/j.jsmc.2022.06.012

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to Sleep Medicine Clinics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Arand D.
        • Bonnet M.
        • Hurwitz T.
        • et al.
        The clinical use of the MSLT and MWT.
        Sleep. 2005; 28: 123-144
        • Pagnin D.
        • de Queiroz V.
        • Carvalho Y.T.
        • et al.
        The rela tion between burnout and sleep disorders in medi cal students.
        Acad Psychiatry. 2014; 38: 438-444
        • Swanson L.M.
        • Arnedt J.T.
        • Rosekind M.R.
        • et al.
        Sleep disorders and work performance: findings from the 2008 National Sleep Foundation Sleep in America poll.
        J Sleep Res. 2011; 20: 487-494
        • Young T.B.
        Epidemiology of daytime sleepiness: definitions, symptomatology, and prevalence.
        J Clin Psychiatry. 2004; 65: 12-16
        • Wu S.
        • Wang R.
        • Ma X.
        • et al.
        Excessive daytime sleepiness assessed by the Epworth Sleepiness Scale and its association with health related quality of life: a population-based study in China.
        BMC Public Health. 2012; 12: 849
        • Plante D.T.
        • Finn L.A.
        • Hagen E.W.
        • et al.
        Longitudinal associations of hypersomnolence and depression in the Wisconsin sleep cohort study.
        J Affect Disord. 2017; 207: 197-202
        • Roth T.
        Effects of excessive daytime sleepiness and fatigue on overall health and cognitive func-tion.
        J Clin Psychiatry. 2015; 76: e1145
        • Garbarino S.
        • Durando P.
        • Guglielmi O.
        • et al.
        Sleep apnea, sleep debt and daytime sleepiness are independently associated with road accidents. A cross-sectional study on truck drivers.
        PLoS One. 2016; 11: e0166262
        • Murray B.J.
        A practical approach to excessive day time sleepiness: a focused review.
        Can Respir J. 2016; 2016: 4215938
        • Doyle J.B.
        • Daniels L.E.
        Symptomatic treatment for narcolepsy.
        J Am Med Assoc. 1931; 96: 1370-1372
        • Akimoto H.
        • Honda Y.
        • Takahashi Y.
        Pharmacotherapy in narcolepsy.
        Dis Nerv Syst. 1960; 21: 704-706
        • Guilleminault C.
        • Carskadon M.
        • Dement W.C.
        On the treatment of rapid eye movement narcolepsy.
        Arch Neurol. 1974; 30: 90-93
        • Parkes J.D.
        • Baraitser M.
        • Marsden C.D.
        • et al.
        Natural history, symptoms and treatment of the narcoleptic syndrome.
        Acta Neurol Scand. 1975; 52: 337-353
        • Passouant P.
        • Billiard M.
        [Narcolepsy].
        Rev Prat. 1976; 26: 1917-1923
        • ICSD-3
        International classification of sleep disor-ders.
        3rd edition. American Sleep Disorders Association, Rochester (MN)2014 (Medicine AAoS)
        • Arnulf I.
        Kleine-levin syndrome.
        Sleep Med Clin. 2015; 10: 151-161
        • Medicine AAoS
        International classification of sleep disorders.
        3rd edition. American Acad emy of Sleep Medicine, Daren (IL)2014
        • Hublin C.
        • Kaprio J.
        • Partinene M.
        • et al.
        The preva lence of narcolepsy: an epidemiological study of the Finnish twin cohort.
        Ann Neurol. 1994; 35: 709-716
      1. TashiroT, KanbayashiT, HishikawaY. An epidemio logical study of narcolepsy in Japanese. Paper pre sented at: The 4th International Symposium on Narcolepsy. Tokyo, Japan, June 16-17, 1994. p. 13.

        • Dauvilliers Y.
        • Montplaisir J.
        • Molinari N.
        • et al.
        Age at onset of narcolepsy in two large populations of pa tients in France and Quebec.
        Neurology. 2001; 57: 2029-2033
        • Nishino S.
        • Mignot E.
        Pharmacological aspects of human and canine narcolepsy.
        Prog Neurobiol. 1997; 52: 27-78
        • Pizza F.
        • Contardi S.
        • Mondini S.
        • et al.
        Daytime sleepiness and driving performance in patients with obstructive sleep apnea: comparison of the MSLT, the MWT, and a simulated driving task.
        Sleep. 2009; 32: 382-391
        • Littner M.R.
        • Kushida C.
        • Wise M.
        • et al.
        Practice pa rameters for clinical use of the multiple sleep la-tency test and the maintenance of wakefulness test.
        Sleep. 2005; 28: 113-121
        • Sullivan S.S.
        • Kushida C.A.
        Multiple sleep latency test and maintenance of wakefulness test.
        Chest. 2008; 134: 854-861
        • Scammell T.E.
        Narcolepsy.
        N Engl J Med. 2015; 373: 2654-2662
        • Dauvilliers Y.
        • Billiard M.
        • Montplaisir J.
        Clinical as-pects and pathophysiology of narcolepsy.
        Clin Neurophysiol. 2003; 114: 2000-2017
        • Guilleminault C.
        • Kryger M.H.
        • Roth T.
        • et al.
        Narco lepsy syndrome. Principles and practice of sleep medicine.
        2nd edition. WB Saunders, Philadelphia1994: 549-561
        • Juji T.
        • Satake M.
        • Honda Y.
        • et al.
        HLA antigens in Japanese patients with narcolepsy. All the patients were DR2 positive.
        Tissue Antigens. 1984; 24: 316-319
        • Gelb M.
        • Guilleminault C.
        • Kraemer H.
        • et al.
        Stability of cataplexy over several months-information for the design of therapeutic trials.
        Sleep. 1994; 17: 265-273
        • Hishikawa Y.
        • Wakamatsu H.
        • Furuya E.
        • et al.
        Sleep satiation in narcoleptic patients.
        Electroencephalogr Clin Neurophysiol. 1976; 41: 1-18
        • Broughton R.
        • Dunham W.
        • Newman J.
        • et al.
        Ambulatory 24 hour sleep-wake monitoring in narcolepsy-cataplexy compared to matched con- trol.
        Electroencephalogr Clin Neurophysiol. 1988; 70: 473-481
        • Montplaisir J.
        • Billard M.
        • Takahashi S.
        • et al.
        Twenty- four-hour recording in REM-narcoleptics with spe- cial reference to nocturnal sleep disruption.
        Biol Psychiatry. 1978; 13: 78-89
        • Godbout R.
        • Montplaisir J.
        Comparison of sleep pa rameters in narcoleptics with and without periodic movements of sleep.
        in: Koella W.P. Ruther E. Schulz H. Sleep '84. Gustav Fischer Verlag, New York1985: 380-382
        • Mosko S.S.
        • Shampain D.S.
        • Sassin J.F.
        Nocturnal REM latency and sleep disturbance in narcolepsy.
        Sleep. 1984; 7: 115-125
        • Mayer G.
        • Pollmächer T.
        • Meier-Ewert K.
        • et al.
        Zur Einschatzung des Behinderungsgrades bei Narkolepsie.
        Gesundheitswesen. 1993; 55: 337-342
        • Schenck C.H.
        • Mahowald M.W.
        Motor dyscontrol in narcolepsy: rapid-Eye-Movement (REM) sleep without atonia and REM sleep behavior disorder.
        Ann Neurol. 1992; 32: 3-10
        • Chokroverty S.
        Sleep apnea in narcolepsy.
        Sleep. 1986; 9: 250-253
      2. Guilleminault C. Dement W.C. Passouant P. Narcolepsy. Spectrum Publications, New York1976 (Advances in Sleep Research; No. 3)
        • Juji T.
        • Matsuki K.
        • Tokunaga K.
        • et al.
        Narcolepsy and HLA in the Japanese.
        Ann N Y Acad Sci. 1988; 540: 106-114
        • Nishino S.
        • Ripley B.
        • Overeem S.
        • et al.
        Hypocretin (orexin) deficiency in human narcolepsy.
        Lancet. 2000; 355: 39-40
        • Mignot E.
        • Lammers G.J.
        • Ripley B.
        • et al.
        The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias.
        Arch Neurol. 2002; 59: 1553-1562
        • ICSD-2
        ICSD-2-International classification of sleep disorders.
        in: Sateia M.J. Diagnostic and cod ing manual. 2nd edition. American Academy of Sleep Medicine, Westchester (IL)2005: 38-43
        • Mignot E.
        • Hayduk R.
        • Black J.
        • et al.
        HLA DQB1∗0602 is associated with cataplexy in 509 narcoleptic patients.
        Sleep. 1997; 20: 1012-1020
        • Dauvilliers Y.
        • Maret S.
        • Bassetti C.
        • et al.
        A monozygotic twin pair discordant for narcolepsy and CSF hypocre- tin-1.
        Neurology. 2004; 62: 2137-2138
        • Ripley B.
        • Fujiki N.
        • Okura M.
        • et al.
        Hypocretin levels in sporadic and familial cases of canine narco lepsy.
        Neurobiol Dis. 2001; 8: 525-534
        • Thannickal T.C.
        • Nienhuis R.
        • Siegel J.M.
        Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy.
        Sleep. 2009; 32: 993-998
        • Garma L.
        • Marchand F.
        Non-pharmacological ap- proaches to the treatment of narcolepsy.
        Sleep. 1994; 17: S97-S102
        • Roehrs T.
        • Zorick F.
        • Wittig R.
        • et al.
        Alerting effects of naps in patients with narcolepsy.
        Sleep. 1986; 9: 194-199
        • Rogers A.E.
        Problems and coping strategies identi- fied by narcoleptic patients.
        J Neurosurg Nurs. 1984; 16: 326-334
        • Morgenthaler T.I.
        • Kapur V.K.
        • Brown T.
        • et al.
        Practice parameters for the treatment of narcolepsy and other hypersomnias of central origin.
        Sleep. 2007; 30: 1705-1711
        • Hirai N.
        • Nishino S.
        Recent advances in the treat ment of narcolepsy.
        Curr Treat Options Neurol. 2011; 13: 437-457
        • Mitler M.M.
        • Aldrich M.S.
        • Koob G.F.
        • et al.
        Narcolepsy and its treatment with stimulants. ASDA standards of practice.
        Sleep. 1994; 17: 352-371
        • Mitler M.M.
        • Hajdukovic R.
        Relative efficacy of drugs for the treatment of sleepiness in narcolepsy.
        Sleep. 1991; 14: 218-220
        • Rogers A.E.
        • Aldrich M.S.
        • Berrios A.M.
        • et al.
        Compli ance with stimulant medications in patients with narcolepsy.
        Sleep. 1997; 20: 28-33
        • Auger R.R.
        • Goodman S.H.
        • Silber M.H.
        • et al.
        Risks of high-dose stimulants in the treatment of disorders of excessive somnolence: a case-control study.
        Sleep. 2005; 28: 667-672
        • Nishino S.
        • Okuro M.
        Armodafinil for excessive day time sleepiness.
        Drugs Today (Barc). 2008; 44: 395-414
        • Darwish M.
        • Kirby M.
        • Hellriegel E.T.
        • et al.
        Armodafinil and modafinil have substantially different pharma cokinetic profiles despite having the same terminal half-lives: analysis of data from three randomized, single-dose, pharmacokinetic studies.
        Clin Drug Investig. 2009; 29: 613-623
      3. Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Moda finil in Narcolepsy Multicenter Study Group.
        Ann Neurol. 1998; 43: 88-97
      4. Randomized trial of modafinil as a treatment for the excessive daytime somnolence of narcolepsy: US Modafinil in Narcolepsy Multicenter Study Group.
        Neurology. 2000; 54: 1166-1175
        • Harsh J.R.
        • Hayduk R.
        • Rosenberg R.
        • et al.
        The effi cacy and safety of armodafinil as treatment for adults with excessive sleepiness associated with narcolepsy.
        Curr Med Res Opin. 2006; 22: 761-774
        • United States Department of Justice
        Drug enforce ment administration. Drug scheduling.
        (Available at:) (Accessed February 10, 2017)
        • Roth T.
        • Schwartz J.R.
        • Hirshkowitz M.
        • et al.
        Evalua tion of the safety of modafinil for treatment of excessive sleepiness.
        J Clin Sleep Med. 2007; 3: 595-602
        • U.S. Food & Drug Administration
        Drug safety. Medication guide.
        (Available at:) (Accessed February 11, 2017)
        • Schwartz J.R.
        • Feldman N.T.
        • Bogan R.K.
        • et al.
        Dosing regimen effects of modafinil for improving daytime wakefulness in patients with narcolepsy.
        Clin Neuropharmacol. 2003; 26: 252-257
      5. Cephalon, Inc. FDA approval of NUVIGIL.
        (Available at:) (Accessed February 11, 2017)
        • Mignot E.
        • Nishino S.
        • Guilleminault C.
        • et al.
        Modafi- nil binds to the dopamine uptake carrier site with low affinity.
        Sleep. 1994; 17: 436-437
        • Nishino S.
        • Mao J.
        • Sampathkumaran R.
        • et al.
        Increased dopaminergic transmission mediates the wake-promoting effects of CNS stimulants.
        Sleep Res Online. 1998; 1: 49-61
        • Dopheide M.M.
        • Morgan R.E.
        • Rodvelt K.R.
        • et al.
        Mod afinil evokes striatal [(3)H]dopamine release and alters the subjective properties of stimulants.
        Eur J Pharmacol. 2007; 568: 112-123
        • Wisor J.P.
        • Nishino S.
        • Sora I.
        • et al.
        Dopaminergic role in stimulant-induced wakefulness.
        J Neurosci. 2001; 21: 1787-1794
        • Qu W.M.
        • Huang Z.L.
        • Xu X.H.
        • et al.
        Dopaminergic D1 and D2 receptors are essential for the arousal ef- fect of modafinil.
        J Neurosci. 2008; 28: 8462-8469
        • Volkow N.D.
        • Fowler J.S.
        • Logan J.
        • et al.
        Effects of modafinil on dopamine and dopamine transporters in the male human brain: clinical implications.
        JAMA. 2009; 301: 1148-1154
        • Yoss R.E.
        • Daly D.
        Treatment of narcolepsy with ritalin.
        Neurology. 1959; 9: 171-173
        • Kuczenski R.
        • Segal D.S.
        Neurochemistry of amphetamine, in psychopharmacology, toxicology and abuse.
        Academic Press, San Diego (CA)1994: 81-113
        • Leonard B.E.
        • McCartan D.
        • White J.
        • et al.
        Methyl- phenidate: a review of its neuropharmacological, neuropsychological and adverse clinical effects.
        Hum Psychopharmacol. 2004; 19: 151-180
        • Schenk J.O.
        The functioning neuronal transporter for dopamine: kinetic mechanisms and effects of amphetamines, cocaine and methylphenidate.
        Prog Drug Res. 2002; 59: 111-131
        • Nissen S.E.
        ADHD drugs and cardiovascular risk.
        N Engl J Med. 2006; 354: 1445-1448
        • Cooper W.O.
        • Habel L.A.
        • Sox C.M.
        • et al.
        ADHD drugs and serious cardiovascular events in children and young adults.
        N Engl J Med. 2011; 365: 1896-1904
        • Broughton R.
        • Mamelak M.
        The treatment of narcolepsy-cataplexy with nocturnal gamma-hy- droxybutyrate.
        Can J Neurol Sci. 1979; 6: 1-6
        • Group U.S.X.M.S.
        A randomized, double blind, placebo-controlled multicenter trial comparing the effects of three doses of orally administered so- dium oxybate with placebo for the treatment of nar colepsy.
        Sleep. 2002; 25: 42-49
        • Group U.S.X.M.S.
        A 12-month, open-label, multi- center extension trial of orally administered sodium oxybate for the treatment of narcolepsy.
        Sleep. 2003; 26: 31-35
        • Group U.S.X.M.S.
        Sodium oxybate demonstrates long-term efficacy for the treatment of cataplexy in patients with narcolepsy.
        Sleep Med. 2004; 5: 119-123
        • Mamelak M.
        • Scharf M.B.
        • Woods M.
        Treatment of narcolepsy with gamma-hydroxybutyrate. A review of clinical and sleep laboratory findings.
        Sleep. 1986; 9: 285-289
        • Plazzi G.
        • Pizza F.
        • Vandi S.
        • et al.
        Impact of acute administration of sodium oxybate on nocturnal sleep polysomnography and on multiple sleep la tency test in narcolepsy with cataplexy.
        Sleep Med. 2014; 15: 1046-1054
        • Mack R.B.
        Love potion number 8 1/2. Gamma- hydroxybutyrate poisoning.
        N C Med J. 1993; 54: 232-233
        • Wong C.G.
        • Gibson K.M.
        • Snead 3rd, O.C.
        From the street to the brain: neurobiology of the recreational drug gamma-hydroxybutyric acid.
        Trends Pharmacol Sci. 2004; 25: 29-34
        • Nicholson K.L.
        • Balster R.L.
        GHB: a new and novel drug of abuse.
        Drug Alcohol Depend. 2001; 63: 1-22
        • Black J.
        • Houghton W.C.
        Sodium oxybate improves excessive daytime sleepiness in narcolepsy.
        Sleep. 2006; 29: 939-946
        • Robinson D.M.
        • Keating G.M.
        Sodium oxybate: a re- view of its use in the management of narcolepsy.
        CNS Drugs. 2007; 21: 337-354
        • Alshaikh M.K.
        • Tricco A.C.
        • Tashkandi M.
        • et al.
        Sodium oxybate for narcolepsy with cataplexy: systematic review and meta-analysis.
        J Clin Sleep Med. 2012; 8: 451-458
        • Thorpy M.J.
        Update on therapy for narcolepsy.
        Curr Treat Options Neurol. 2015; 17: 347
        • Palatini P.
        • Tedeschi L.
        • Frison G.
        • et al.
        Dose-depen- dent absorption and elimination of gamma- hydroxybutyric acid in healthy volunteers.
        Eur J Clin Pharmacol. 1993; 45: 353-356
        • Wang Y.G.
        • Swick T.J.
        • Carter L.P.
        • et al.
        Safety over view of postmarketing and clinical experience of sodium oxybate (Xyrem): abuse, misuse, depen dence, and diversion.
        J Clin Sleep Med. 2009; 5: 365-371
        • Administration tUSFaD
        (Available at:) (Accessed February 9, 2017)
        • Saini P.
        • Rye D.B.
        Hypersomnia: evaluation, treat ment, and social and economic aspects.
        Sleep Med Clin. 2017; 12: 47-60
        • Maitre M.
        • Klein C.
        • Mensah-Nyagan A.G.
        Mecha nisms for the specific properties of gamma- hydroxybutyrate in brain.
        Med Res Rev. 2016; 36: 363-388
        • Pardi D.
        • Black J.
        g-hydroxybutyrate/sodium oxy bate.
        CNS drugs. 2006; 20: 993-1018
        • Andriamampandry C.
        • Taleb O.
        • Viry S.
        • et al.
        Cloning and characterization of a rat brain receptor that binds the endogenous neuromodulator gamma- hydroxybutyrate (GHB).
        Faseb J. 2003; 17: 1691-1693
        • Wu M.F.
        • Gulyani S.A.
        • Yau E.
        • et al.
        Locus coeruleus neurons: cessation of activity during cataplexy.
        Neuroscience. 1999; 91: 1389-1399
        • Szabadi E.
        GHB for cataplexy: possible mode of action.
        J Psychopharmacol. 2015; 29: 744-749
        • Nishino S.
        • Ripley B.
        • Mignot E.
        • et al.
        CSF hypocretin-1 levels in schizophrenics and controls: relationship to sleep architecture.
        Psychiatry Res. 2002; 110: 1-7
        • Shiba T.
        Wake promoting effects of thioperamide, a histamine H3 antagonist in orexin/ataxin-3 narco leptic mice.
        Sleep. 2004; 27: A241-A242
        • Parmentier R.
        • Anaclet C.
        • Guhennec C.
        • et al.
        The brain H3-receptor as a novel therapeutic target for vigilance and sleep-wake disorders.
        Biochem Pharmacol. 2007; 73: 1157-1171
        • Lin J.S.
        • Dauvilliers Y.
        • Arnulf I.
        • et al.
        An inverse agonist of the histamine H(3) receptor improves wakefulness in narcolepsy: studies in orexin-/- mice and patients.
        Neurobiol Dis. 2008; 30: 74-83
        • Dauvilliers Y.
        • Bassetti C.
        • Lammers G.J.
        • et al.
        Pitoli- sant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial.
        Lancet Neurol. 2013; 12: 1068-1075
        • Sharif N.A.
        • To Z.P.
        • Whiting R.L.
        Analogs of thyrotropin- releasing hormone (TRH): receptor affinities in brains, spinal cords, and pituitaries of different spe- cies.
        Neurochem Res. 1991; 16: 95-103
        • Leu-Semenescu S.
        • Nittur N.
        • Golmard J.L.
        • et al.
        Ef fects of pitolisant, a histamine H3 inverse agonist, in drug-resistant idiopathic and symptomatic hy persomnia: a chart review.
        Sleep Med. 2014; 15: 681-687
      6. U.S. Food and Drug Administration. SUNOSI (solriamfetol): Highlights of prescribing information. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/211230s000lbl.pdf. Cited July 1, 2022.

        • Bogan R.K.
        • Feldman N.
        • Emsellem H.A.
        • et al.
        Effect of oral JZP-110 (ADX-N05) treatment on wakefulness and sleepiness in adults with narcolepsy.
        Sleep Med. 2015; 16: 1102-1108
        • Ruoff C.
        • Swick T.J.
        • Doekel R.
        • et al.
        Effect of oral JZP-110 (ADX-N05) on wakefulness and sleepiness in adults with narcolepsy: a phase 2b study.
        Sleep. 2016; 39: 1379-1387
        • Gandhi K.D.
        • Mansukhani M.P.
        • Silber M.H.
        • et al.
        Excessive daytime sleepiness: a clinical review.
        Mayo Clin Proc. 2021; 96: 1288-1301
        • Swick T.J.
        Treatment paradigms for cataplexy in narcolepsy: past, present, and future.
        Nat Sci Sleep. 2015; 7: 159-169
        • Santarsieri D.
        • Schwartz T.L.
        Antidepressant efficacy and side-effect burden: a quick guide for clini cians.
        Drugs Context. 2015; 4: 212290
        • Thase M.E.
        Depression, sleep, and antidepres sants.
        J Clin Psychiatry. 1998; 59: 55-65
        • Roth B.
        Narkolepsie und hypersomnie.
        VEB Verlag Volk und Gesundheit, Berlin1962
        • Bassetti C.
        • Aldrich M.S.
        Idiopathic hypersomnia. A series of 42 patients.
        Brain. 1997; 120: 1423-1435
        • Bassetti C.
        • Gugger M.
        • Bischof M.
        • et al.
        The narco- leptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A).
        Sleep Med. 2003; 4: 7-12
        • Vernet C.
        • Leu-Semenescu S.
        • Buzare M.A.
        • et al.
        Subjective symptoms in idiopathic hypersomnia: beyond excessive sleepiness.
        J Sleep Res. 2010; 19: 525-534
      7. International classification of sleep disorders: diag nostic and coding manual. 3rd edition. American Academy of Sleep Medicine, Westches ter (IL)2014
        • Mayer G.
        • Benes H.
        • Young P.
        • et al.
        Modafinil in the treatment of idiopathic hypersomnia without long sleep time-a randomized, double-blind, placebo- controlled study.
        J Sleep Res. 2015; 24: 74-81
        • Billiard M.
        • Sonka K.
        Idiopathic hypersomnia.
        Sleep Med Rev. 2016; 29: 23-33
        • Leu-Semenescu S.
        • Louis P.
        • Arnulf I.
        Benefits and risk of sodium oxybate in idiopathic hypersomnia versus narcolepsy type 1: a chart review.
        Sleep Med. 2016; 17: 38-44
        • Nishino S.
        • Kanbayashi T.
        Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin/orexin system.
        Sleep Med Rev. 2005; 9: 269-310
        • Verma A.
        • Anand V.
        • Verma N.P.
        Sleep disorders in chronic traumatic brain injury.
        J Clin Sleep Med. 2007; 3: 357-362
        • Mathias J.L.
        • Alvaro P.K.
        Prevalence of sleep distur bances, disorders, and problems following trau matic brain injury: a meta-analysis.
        Sleep Med. 2012; 13: 898-905
        • Baumann C.R.
        • Stocker R.
        • Imhof H.G.
        • et al.
        Hypocre- tin-1 (orexin A) deficiency in acute traumatic brain injury.
        Neurology. 2005; 65: 147-149
        • Kaiser P.R.
        • Valko P.O.
        • Werth E.
        • et al.
        Modafinil ame liorates excessive daytime sleepiness after trau matic brain injury.
        Neurology. 2010; 75: 1780-1785
        • Jha A.
        • Weintraub A.
        • Allshouse A.
        • et al.
        A randomized trial of modafinil for the treatment of fatigue and excessive daytime sleepiness in individuals with chronic traumatic brain injury.
        J Head Trauma Rehabil. 2008; 23: 52-63
        • Menn S.J.
        • Yang R.
        • Lankford A.
        Armodafinil for the treatment of excessive sleepiness associated with mild or moderate closed traumatic brain injury: a 12-week, randomized, double-blind study followed by a 12-month open-label extension.
        J Clin Sleep Med. 2014; 10: 1181-1191
        • Braga-Neto P.
        • da Silva-Junior F.P.
        • Sueli Monte F.
        • et al.
        Snoring and excessive daytime sleepiness in Par kinson's disease.
        J Neurol Sci. 2004; 217: 41-45
        • Gjerstad M.D.
        • Alves G.
        • Wentzel-Larsen T.
        • et al.
        Excessive daytime sleepiness in Parkinson dis- ease: is it the drugs or the disease?.
        Neurology. 2006; 67: 853-858
        • Verbaan D.
        • van Rooden S.M.
        • Visser M.
        • et al.
        Nighttime sleep problems and daytime sleepi- ness in Parkinson's disease.
        Mov Disord. 2008; 23: 35-41
        • Adler C.H.
        • Caviness J.N.
        • Hentz J.G.
        • et al.
        Random- ized trial of modafinil for treating subjective day- time sleepiness in patients with Parkinson's disease.
        Mov Disord. 2003; 18: 287-293
        • Hogl B.
        • Saletu M.
        • Brandauer E.
        • et al.
        Modafinil for the treatment of daytime sleepiness in Parkinson's disease: a double-blind, randomized, crossover, placebo-controlled polygraphic trial.
        Sleep. 2002; 25: 905-909
        • Ondo W.G.
        • Fayle R.
        • Atassi F.
        • et al.
        Modafinil for daytime somnolence in Parkinson's disease: double blind, placebo controlled parallel trial.
        J Neurol Neurosurg Psychiatr. 2005; 76: 1636-1639
        • Ondo W.G.
        • Perkins T.
        • Swick T.
        • et al.
        Sodium oxy- bate for excessive daytime sleepiness in Parkinson disease: an open-label polysomnographic study.
        Arch Neurol. 2008; 65: 1337-1340
        • Fisone G.
        • Borgkvist A.
        • Usiello A.
        Caffeine as a psy- chomotor stimulant: mechanism of action.
        Cell Mol Life Sci. 2004; 61: 857-872
        • Porkka-Heiskanen T.
        • Strecker R.E.
        • Thakkar M.
        • et al.
        Adenosine: a mediator of the sleep-inducing ef- fects of prolonged wakefulness.
        Science. 1997; 276: 1265-1268
        • Nawrot P.
        • Jordan S.
        • Eastwood J.
        • et al.
        Effects of caffeine on human health.
        Food Addit Contam. 2003; 20: 1-30
        • Barone J.J.
        • Roberts H.R.
        Caffeine consumption.
        Food Chem Toxicol. 1996; 34: 119-129
        • Mieda M.
        • Willie J.T.
        • Hara J.
        • et al.
        Orexin peptides prevent cataplexy and improve wakefulness in an orexin neuron-ablated model of narcolepsy in mice.
        Proc Natl Acad Sci U S A. 2004; 101: 4649-4654
        • Schatzberg S.J.
        • Cutter-Schatzberg K.
        • Nydam D.
        • et al.
        The effect of hypocretin replacement therapy in a 3-year-old Weimaraner with narcolepsy.
        J Vet Intern Med. 2004; 18: 586-588
        • Kantor S.
        • Mochizuki T.
        • Janisiewicz A.M.
        • et al.
        Orexin neurons are necessary for the circadian control of REM sleep.
        Sleep. 2009; 32: 1127-1134
        • Deadwyler S.A.
        • Porrino L.
        • Siegel J.M.
        • et al.
        Systemic and nasal delivery of orexin-A (Hypocretin-1) re duces the effects of sleep deprivation on cognitive performance in nonhuman primates.
        J Neurosci. 2007; 27: 14239-14247
        • Nagahara T.
        • Saitoh T.
        • Kutsumura N.
        • et al.
        Design and synthesis of non-peptide, selective orexin re- ceptor 2 agonists.
        J Med Chem. 2015; 58: 7931-7937
        • Kimura H.
        • Ishikawa T.
        • Suzuki M.
        A novel, orally available orexin 2 receptor-selective agonist, tak-994, ameliorates narcolepsy-like symptoms in narcolepsy mouse models.
        Sleep Med. 2019; 64: S199
        • Yukitake H.
        • fujimoto T.
        • Ishikawa T.
        • et al.
        TAK-925, an orexin 2 receptor-selective agonist, shows robust wake-promoting effects in mice.
        Pharmacol Biochem Behav. 2019; 187: 172794
        • Evans R.
        • Hazel J.
        • Faessel H.
        • et al.
        Results of a phase 1, 4-period crossover, placebo-controlled, randomized, single dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-925, a novel orexin 2 receptor agonist, in sleep-deprived healthy adults, utilizing modafinil as an active comparator.
        Sleep Med. 2019; 64: S106
        • Baier P.C.
        • Hallschmid M.
        • Seeck-Hirschner M.
        • et al.
        Effects of intranasal hypocretin-1 (orexin A) on sleep in narcolepsy with cataplexy.
        Sleep Med. 2011; 12: 941-946
        • Mishima K.
        • Fujiki N.
        • Yoshida Y.
        • et al.
        Hypocretin re ceptor expression in canine and murine narcolepsy models and in hypocretin-ligand deficient human narcolepsy.
        Sleep. 2008; 31: 1119-1126
        • Kawashima M.
        • Lin L.
        • Tanaka S.
        • et al.
        Anti-Tribbles homolog 2 (TRIB2) autoantibodies in narcolepsy are associated with recent onset of cataplexy.
        Sleep. 2010; 33: 869-874
        • Dauvilliers Y.
        • Abril B.
        • Mas E.
        • et al.
        Normalization of hypocretin-1 in narcolepsy after intravenous immu noglobulin treatment.
        Neurology. 2009; 73: 1333-1334
        • Dauvilliers Y.
        • Carlander B.
        • Rivier F.
        • et al.
        Successful management of cataplexy with intravenous immu- noglobulins at narcolepsy onset.
        Ann Neurol. 2004; 56: 905-908
        • Ueno R.
        • Honda K.
        • Inoue S.
        • et al.
        Prostaglandin D2, a cerebral sleep-inducing substance in rats.
        Proc Natl Acad Sci U S A. 1983; 80: 1735-1737
        • Huang Z.L.
        • Urade Y.
        • Hayaishi O.
        Prostaglandins and adenosine in the regulation of sleep and wakefulness.
        Curr Opin Pharmacol. 2007; 7: 33-38
        • Jordan W.
        • Tumani H.
        • Cohrs S.
        • et al.
        Narcolepsy increased L-PGDS (beta-trace) levels correlate with excessive daytime sleepiness but not with cat aplexy.
        J Neurol. 2005; 252: 1372-1378
        • Sagawa Y.
        • Sato M.
        • Sakai N.
        • et al.
        Wake-promoting effects of ONO-4127Na, a prostaglandin DP1 re ceptor antagonist, in hypocretin/orexin deficient narcoleptic mice.
        Neuropharmacology. 2016; 110: 268-276
        • Riehl J.
        • Honda K.
        • Kwan M.
        • et al.
        Chronic oral administration of CG-3703, a thyrotropin releasing hormone analog, increases wake and decreases cataplexy in canine narcolepsy.
        Neuropsychopharmacology. 2000; 23: 34-45
        • Nicoll R.A.
        Excitatory action of TRH on spinal moto- neurones.
        Nature. 1977; 265: 242-243
        • Nishino S.
        • Arrigoni J.
        • Shelton J.
        • et al.
        Effects of thyrotropin-releasing hormone and its analogs on daytime sleepiness and cataplexy in canine narco lepsy.
        J Neurosci. 1997; 17: 6401-6408
        • Sharp T.
        • Bennett G.W.
        • Marsden C.A.
        Thyrotrophin- releasing hormone analogues increase dopamine release from slices of rat brain.
        J Neurochem. 1982; 39: 1763-1766
        • Heuer H.
        • Schafer M.K.
        • O'Donnell D.
        • et al.
        Expres- sion of thyrotropin-releasing hormone receptor 2 (TRH-R2) in the central nervous system of rats.
        J Comp Neurol. 2000; 428: 319-336
        • Keller H.H.
        • Bartholini G.
        • Pletscher A.
        Enhancement of cerebral noradrenaline turnover by thyrotropin- releasing hormone.
        Nature. 1974; 248: 528-529
      8. Broberger C. Neurotransmitters switching the thal amus between sleep and arousal: functional ef fects and cellular mechanism. New Frontiers in Neuroscience Research. Showa University Interna tional Symposium for Life Science. 1st Annual Meeting Showa University Kamijo Hall. Tokyo, August 31, 2004.

        • Mignot E.
        • Nishino S.
        Emerging therapies in narco- lepsy-cataplexy.
        Sleep. 2005; 28: 754-763
        • Okura M.
        • Riehl J.
        • Mignot E.
        • et al.
        Sulpiride, a D2/D3 blocker, reduces cataplexy but not REM sleep in canine narcolepsy.
        Neuropsychopharmacology. 2000; 23: 528-538
        • Nishino S.
        • Mignot E.
        Narcolepsy and cataplexy.
        Handb Clin Neurol. 2011; 99: 783-814
      9. Takeda Pharmaceutical Company Limited. Clinical Trial Summary October 2021 (Accessed 6 July 2022).

      10. Takeda Pharmaceutical Company Limited. Takeda Provides Update on TAK-994 Clinical Program (Accessed 6 July 2022).